Clinical Trials Browser

Phase 2/3 × Lorazepam × Clear all

NCT03743649 2025-12-26

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Phase 2/3 Active not recruiting

Delirium, Neoplasm Metastasis, Recurrence